BioSpace News Archive

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare diseases, today announced results from a late-breaker poster presentation at The Digital International Liver Congress™ 2020 of end of treatment results of the Phase 2 LIFT Lambda

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Mr. Paul Clark to Agenus’ Board of Directors.

Today, Inova Software and the Biotechnology Innovation Organization (BIO) are announcing the first international series of virtual partnering events focused on three critical therapeutic areas with great unmet need - oncology, neuroscience and infectious diseases, happening until the end of the year.

Transparency Life Sciences (TLS) today announced the addition of Jennifer Levin Carter M.D., MPH, MBA to the advisory board. Dr. Carter is a healthcare executive and entrepreneur with particular expertise in precision medicine, genomics, digital health and AI applications to healthcare.

Nihon Kohden, a U.S. market leader in precision medical products and services, today announced the launch of Polysmith 12 polysomnography software.

Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers, today announced the appointment of Dov Goldstein, M.D., as its first chief financial and business officer.

The Dow Chemical Company, a wholly-owned subsidiary of Dow Inc., announced the early results of its previously-announced cash tender offers to purchase certain of its debt securities and certain debt securities of Union Carbide Corporation, a wholly-owned subsidiary of TDCC, listed in the table below in an aggregate purchase price of up to $550 million.

Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA)

Virpax® Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services.

Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of dedicated service, Ms. Moore has decided to retire and pursue personal interests